<DOC>
	<DOCNO>NCT00700284</DOCNO>
	<brief_summary>The purpose trial evaluate safety feasibility use vaginal ring deliver candidate microbicide TMC120 ( dapivirine ) . Twelve woman initially underwent 7-day exposure placebo ring contain investigational agent . They undergo 7-day exposure ring contain 120 mg TMC120 ( dapivirine ) . Feasibility assess term safety tolerability well drug delivery .</brief_summary>
	<brief_title>Feasibility Study Vaginal Ring Delivery TMC120 ( Dapivirine )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Female , 1850 year , inclusive Willing able provide write informed consent HIVuninfected otherwise healthy Willing abstain sexual activity use vaginal product participate trial Currently use oral contraceptive pregnancy prevention Willing use oral contraceptive need avoid menstruation take part trial History alcoholism , drug abuse , psychosis , antagonistic personality , poor motivation , emotional intellectual problem likely invalidate inform consent process adversely impact compliance protocol requirement . History allergy TMC120 constituent vaginal ring . History hypersensitivity propofol , contraindication general anesthesia sedation History diagnosis and/or treatment sexually transmit disease within last three month . History genital tract surgery within last month Currently pregnant breastfeeding , within two month last pregnancy outcome Currently within one month participate clinical research trial Current ( screen ) diagnosis genital infection Current vulvar vaginal symptom Current noniatrogenic pelvic/colposcopic exam finding involve deep epithelial disruption</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>HIV-I</keyword>
	<keyword>Reverse transcriptase inhibitor</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>